Product Data Sheet

Tubulin inhibitor 41

Cat. No.:HY-161256CAS No.:2770273-12-4Molecular Formula: $C_{20}H_{15}N_3O$ Molecular Weight:313.35

Target: Microtubule/Tubulin; Apoptosis

Pathway: Cell Cycle/DNA Damage; Cytoskeleton; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	Tubulin inhibitor 41 (Compd D19), a promising anti-GBM (glioblastoma) lead compound and tublin inhibitor with BBB permeability, induces G2/M phase arrest, resulted in cell apoptosis and inhibits the migration of U87 cells ^[1] .
In Vitro	Tubulin inhibitor 41 (Compd D19) displays positive antiproliferative activity against U87 cancer cell line (IC $_{50}$ = 0.90 \pm 0.03 μ M). Tubulin inhibitor 41 (Compd D19) could degrade the intracellular tubulin skeletons ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Tubulin inhibitor 41 (Compd D19, 5 mg/kg and 10 mg/kg) dose-dependently inhibits the tumor growth of orthotopic glioma xenografts model (GL261-Luc) and effectively prolonged the survival time of mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Haoyi Yang, et al. Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent. Eur J Med Chem. 2024 Feb 8:267:116205.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA